The first patient in a pivotal Phase III trial of the StrataGraft skin tissue graft has been enrolled by Mallinckrodt. The study, which is part of a five-year contract with the Biomedical Advanced Research and Development Authority, seeks to assess treatment outcomes from use of the regenerative skin tissue in patients who have 3% to 49% total body surface area of severe thermal burns.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.